<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859962</url>
  </required_header>
  <id_info>
    <org_study_id>PPI-668-201</org_study_id>
    <nct_id>NCT01859962</nct_id>
  </id_info>
  <brief_title>Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C</brief_title>
  <official_title>A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presidio Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Presidio Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to provide a preliminary assessment of the safety and effectiveness of
      the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the
      treatment of chronic hepatitis C virus infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients achieving sustained viral response (SVR)</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with &quot;virologic relapse&quot; post-treatment, defined as confirmed and quantifiable (&gt;LLOQ) serum HCV RNA in a patient who achieved non-detectable serum HCV RNA by the end of treatment</measure>
    <time_frame>up to 24 weeks post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with confirmed viral breakthrough during study treatment</measure>
    <time_frame>up to 12 weeks of study treatment</time_frame>
    <description>&quot;Confirmed viral breakthrough&quot; is defined as a &gt; 1 log increase in HCV RNA from post-Baseline nadir value or confirmed increase in HCV RNA ≥LLOQ if HCV RNA previously declined to &lt;LLOQ (detected or not detected), during the 12-week study treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of study participants who receive at least one dose of study drug and who prematurely discontinue study treatment, and proportions prematurely discontinuing treatment for clinical adverse events or laboratory abnormalities</measure>
    <time_frame>up to 12 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of study participants experiencing treatment-emergent adverse events (serious and non-serious) considered to be possibly or probably attributable to study treatment, overall and by body system</measure>
    <time_frame>up to 12 weeks of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPI-668, BI 207127 Dose 1, and Faldaprevir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI-668</intervention_name>
    <arm_group_label>PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_label>PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_label>PPI-668, BI 207127 Dose 1, and Faldaprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 Dose 1</intervention_name>
    <arm_group_label>PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_label>PPI-668, BI 207127 Dose 1, and Faldaprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 Dose 2</intervention_name>
    <arm_group_label>PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir</intervention_name>
    <arm_group_label>PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_label>PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_label>PPI-668, BI 207127 Dose 1, and Faldaprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin</arm_group_label>
    <arm_group_label>PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 207127 Placebo</intervention_name>
    <arm_group_label>PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 to 65 years of age; if females are of childbearing potential, then
             they must be willing to use two non-hormonal methods of birth control

          2. Body weight greater than 40 kg and less than 125 kg

          3. Clinical diagnosis of chronic hepatitis C

          4. Treatment-naïve for hepatitis C: no previous treatment with interferon, pegylated
             interferon, ribavirin, telaprevir, boceprevir, or any investigational therapies for
             hepatitis C

          5. No symptoms or signs of intercurrent illness at Screen (other than those attributable
             to hepatitis C)

          6. No clinically significant abnormalities in the 12-lead electrocardiogram at Screen

          7. Signed informed consent prior to trial participation.

        Exclusion Criteria:

          1. Seropositive for HIV antibody or Hepatitis B Surface Antigen at Screen

          2. Liver disease due to causes other than chronic HCV infection

          3. Symptoms or signs of decompensated liver disease, or evidence of cirrhosis

          4. Any medical condition that may interfere with the absorption, distribution or
             elimination of study drugs

          5. Poorly controlled or unstable hypertension at Screen.

          6. Clinically significant, unstable cardiovascular or pulmonary disease, including
             cardiovascular or pulmonary disease requiring pharmacologic intervention other than
             anti-hypertensive medications, statins, and/or prophylactic aspirin (or similar
             anticoagulant).

          7. Red blood cell disorder, including (but not limited to): thalassemia major or minor,
             sickle cell anemia.

          8. Diabetes Mellitus treated with insulin or hypoglycemic agents

          9. History of asthma requiring hospital admission within the preceding 12 months

         10. History of alcohol abuse or illicit drug use which could interfere with a patient's
             compliance with the protocol requirements, or with the safety or efficacy assessments
             in this study

         11. Patients requiring treatment, during this study, with any of the medications on the
             restricted medications list (provided in the investigator site file), are not eligible
             for this study due to considerations of possible drug interactions with the study drug
             regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel Brown, MD</last_name>
    <role>Study Director</role>
    <affiliation>Presidio Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <disposition_first_submitted>October 20, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 24, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2015</disposition_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver diseases</keyword>
  <keyword>Virus diseases</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>protease inhibitor</keyword>
  <keyword>NS5B polymerase inhibitor</keyword>
  <keyword>NS5A inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

